ABSTRACT
INTRODUCTION
Cardiovascular disease (CVD) is the number one cause of death in women 1, 2 . While there are classical risk factors for CVD that affect both women and men, pre-eclampsia (PE) is a risk factor exclusive to women, increasing the risk of CVD two to seven times in the first 15 years after pregnancy 1, 3, 4 . PE is a pregnancy-related endothelial disorder and is one of the major contributors to maternal and fetal morbidity and mortality, occurring in 3-5% of all pregnancies [5] [6] [7] [8] . PE is the common vascular endpoint of different underlying mechanical and biochemical disorders, mostly conventional cardiovascular risk factors consistent with metabolic syndrome, capable of jeopardizing both placental and endothelial function [9] [10] [11] [12] . As metabolic syndrome and the associated cardiovascular risk are sensitive to lifestyle interventions, timely detection of those specifically at risk may offer effective prevention opportunities for cardiovascular risk management in these women.
In the first year after a pre-eclamptic pregnancy, the prevalence of asymptomatic structural heart disease, defined as preclinical heart failure Stage B (HF-B), is about one in four women 13, 14 . HF-B is considered the stage of heart failure preceding the mortality-related symptomatic and clinical stages, Stages C and D 15, 16 . Endothelial dysfunction correlates with symptomatic heart failure 17, 18 . A few years after PE, endothelial dysfunction remains highly prevalent and it is thought that this asymptomatic vascular condition relates to the increased risk of CVD after PE [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . On the one hand, the unfavorable structural heart alterations after PE may relate to traditional cardiovascular risk factors; on the other hand, they could be a result of endothelial dysfunction 1, 18 . Therefore, in this study, we assessed the relationship between endothelial function, along with components of metabolic syndrome, and asymptomatic structural heart dysfunction in formerly pre-eclamptic women and healthy parous controls.
METHODS
The protocol of this observational study was approved by the Medical Ethics Committee of the Radboud University Medical Center (NL32718.091.10). The procedures followed were in accordance with institutional guidelines and adhered to the principles of the Declaration of 
Study population
At the Radboud University Medical Center, women with a history of PE were evaluated routinely for cardiovascular function at approximately 1 year postpartum. For this study, those women who were at least 4 years postpartum were reinvited by mail to participate in a second follow-up cardiovascular assessment. The study was completed in the east of The Netherlands, where the average socioeconomic status is known to be representative of the country as a whole and where the prevalence of immigrants is low. We included for this study 92 women with a history of PE without comorbidity (diabetes mellitus, autoimmune disease or pre-existing hypertension) prior to their index pregnancy. Nine of these women were excluded due to incomplete echocardiographic work-up, insufficient to diagnose HF-B, and 16 due to an incomplete flow-mediated dilation (FMD) measurement. Controls were recruited by advertisement in local newspapers, schools and childcare centers in the same catchment area as that from which the formerly pre-eclamptic women originated. Forty-seven control women were included with a history of pregnancy uncomplicated by gestational hypertension, PE, HELLP syndrome, fetal growth restriction, placental abruption or intrauterine fetal death. Of these women, nine were excluded due to incomplete echocardiographic work-up, insufficient to diagnose HF-B, and one due to incomplete FMD measurement. Pregnancy charts were checked to ensure that pregnancies were uncomplicated. In total, 67 formerly pre-eclamptic women and 37 control women were included.
PE was diagnosed, according to the criteria set by the International Society of Hypertension in Pregnancy, as new-onset hypertension, defined as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg after 20 weeks' gestation, and proteinuria exceeding 0.3 g/day 29 . Early-onset PE was diagnosed as the development of PE before 34 weeks of gestation. Preterm PE was defined as PE requiring delivery before 37 weeks of gestation.
Five women gave birth to twins. All birth weights were analyzed. Most women in the PE and control groups were of European origin, but two were of Turkish and one was of Moroccan origin. At the time of assessment, none of the women was pregnant, and all had stopped breastfeeding and were not using oral contraceptives. Women who became pregnant after the index pregnancy had to be at least 6 months postpartum to be included in the second follow-up cardiovascular assessment.
Cardiovascular assessment
Each cardiovascular risk evaluation started at 08.00 h in a temperature-controlled room (22 • C), after an overnight fast. Measurements were performed in the follicular phase of the menstrual cycle, between days 3 and 11 after the onset of menses [30] [31] [32] . Participants were not allowed to talk during measurements and external disturbances were kept to a minimum. Measurements were performed following a standardized study protocol by an experienced physician. Cardiovascular screening consisted of measuring body mass (kg; Seca 888 scale, Hamburg, Germany) and height (m) in order to calculate body mass index (BMI). Women rested for at least 15 min before measurement of SBP, DBP, mean arterial pressure (MAP) and heart rate (HR). Measurement lasted for 30 min (at 3-min intervals) and was taken with the woman in the upright sitting position using a semi-automatic oscillometric device (Dinamap Vital Signs Monitor 1846; Critikon, Tampa, FL, USA) with a cuff size recommended for arm circumference. Median values were used for analysis. Hypertension was diagnosed as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or antihypertensive medication being taken. Prehypertension was defined as SBP 120-139 mmHg and/or DBP 80-89 mmHg. Venous blood samples taken at the level of the antecubital vein were analyzed for fasting glucose (mmol/L), fasting insulin (mmol/L) and lipids (mmol/L), including low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides and total cholesterol (Aeroset, Abbot Laboratories, IL, USA). The homeostatic model assessment index for insulin resistance (HOMA IR ) was calculated as insulin (mU/L) × glucose (mmol/L)/22.5 33 . All patients collected their urine in the 24 h before cardiovascular screening. The 24-h urine sample was evaluated for albumin and creatinine to diagnose (micro)albuminuria corrected for creatinine output (g/mol creatinine) (Aeroset). Participants filled out a validated questionnaire consisting of general history, current medication intake, intoxicants (smoking was defined as ≥ 1 cigarette per day), lifestyle factors and family history of CVD (in first line relatives < 60 years of age).
Flow-mediated dilation measurements
Measurement of FMD was used to assess endothelial function as it is a reproducible, accurate and non-invasive method 34, 35 . FMD characterizes the change in artery diameter in response to reactive hyperemia 19 . The resulting increase in shear stress leads to the endothelium releasing vasodilators, including nitric oxide, which cause dilation in a healthy artery 19, 34, 36 . FMD and brachial artery shear pattern measurements were performed under standardized conditions in a temperature-controlled (22 ± 0.5
• C), quiet room, according to recent guidelines 28, 32, 37 . Subjects were supine with the arm placed in an extended position, immobilized with foam, at an angle of ∼80
• from the torso 28, 32 . To induce forearm ischemia, a rapid inflation and deflation pneumatic cuff (D. E. Hokanson, Bellevue, WA, USA) was positioned on the forearm distal to the olecranon 28, 32 . The brachial artery was imaged in the distal one-third of the upper arm (2-5 cm above the antecubital fossa) using a 10-MHz multifrequency linear array probe attached to a high-resolution ultrasound machine (T3000; Terason Corp., Burlington, MA, USA) 28, 32 . Ultrasound was also used to measure continuous Doppler velocity with the lowest possible insonation angle of < 60
•28,32 . Shear rate was calculated as 4 × velocity/diameter 32, 38 . Thereafter, the rapid inflation/deflation forearm cuff was inflated (> 200 mmHg) for 5 min 28, 32 . Diameter and flow recordings were resumed 30 s before deflation of the cuff and continued for 3 min after deflation 32, 37 . To minimize investigator bias, FMD analysis was performed using custom-designed edge-detection and wall-tracking Digital Imaging and Communications in Medicine-based software (National Electrical Manufacturers Association, Rosslyn, VA, USA) 28, 32, 37, 39 . Peak diameter was detected automatically according to an algorithm that is described in detail elsewhere 32, 40 . Using this technique, data can be analyzed with a temporal resolution of 30 Hz and a spatial resolution of ∼0.0065 cm for diameter and ∼1 cm/s for velocity 32 , and FMD has an intraobserver coefficient of repeated measures of 6.7% 39 . Postdeflation shear rate data (derived from simultaneously acquired velocity and diameter measurements at 30 Hz) were used for calculating the area under the shear-rate curve for data up to the point of maximal postdeflation diameter (FMD) for each individual 28, 32 .
Echocardiographic measurements
Echocardiographic measurements were made using a phased-array echocardiographic Doppler system (Vivid 7, GE Vingmed Ultrasound, Horten, Norway). Two-dimensional, M-mode and Doppler echocardiography were performed in accordance with the recommendation of the American Society of Echocardiography (ASE) 41 . Using M-mode in the parasternal long-axis view, we measured left ventricular end-diastolic (LVEDd) and end-systolic (LVESd) diameters (mm), end-diastolic interventricular septum thickness (IVST; mm) and the posterior (inferolateral) wall thickness (PWT; mm). As recommended by the ASE, left ventricular mass (LVM; g) was determined using the formula 0.8 × (1.04((LVEDd + PWT + IVST) 3 − (LVEDd) 3 )) + 0.6, indexed for body surface area 42 . Relative wall thickness (RWT) was computed using the formula (2 × PWT)/LVEDd) 42 . Left ventricular end-diastolic (LVEDV, mL) and end-systolic (LVESV, mL) volumes were determined using the Teichholz formula 43 . Left ventricular ejection fraction (LVEF, %) was calculated using the formula ((LVEDV -LVESV)/(LVEDV)) × 100. Heart rate (HR, bpm) was calculated by multiplying by 60 the reciprocal of the mean of five consecutive RR intervals on the electrocardiogram. Mean aortic velocity time integral (VTI, cm) was calculated by averaging the outer edge tracings of five consecutive continuous wave Doppler registrations of the left ventricular outflow tract velocity. Stroke volume (SV, mL) was computed by taking the product of VTI and mid-systolic cross-sectional area (cm 2 ) at the level of the left ventricular outflow tract in the parasternal long-axis view. Cardiac output (CO, L/min) was calculated by multiplying SV by HR. Assessments were executed offline using EchoPAC PC SW (GE Vingmed Ultrasound) version 6.1.2.
Definition of heart failure Stage A
Heart failure Stage A (HF-A) was defined as the presence of hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or use of antihypertensive medication), atherosclerotic disease, diabetes mellitus (fasting glucose ≥ 6.1 mmol/L), obesity (BMI ≥ 30 kg/m 2 ) or metabolic syndrome 16 . A modified metabolic syndrome was defined, using the WHO criteria, as insulin resistance (fasting insulin ≥ 9.2 mU/L and/or fasting glucose ≥ 6.1 mmol/L and/or HOMA IR ≥ 2.2) and two or more of the following factors: hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 85 mmHg and/or use of antihypertensive medication), obesity (BMI ≥ 30 kg/m 2 ), dyslipidemia (triglycerides ≥ 1.69 mmol/L and/or HDL < 1.0 mmol/L) and/or microalbuminuria (urine albumin to creatinine ratio ≥ 2.5 g/mol creatinine) 44 .
Definition of heart failure Stage B
HF-B was defined, according to the American Heart Association (AHA) 16 , as the presence of a former myocardial infarction, left ventricular hypertrophy (left ventricular mass index (LVMi) > 95 g/m 2 ), concentric remodeling (RWT > 0.42 and LVMi ≤ 95 g/m 2 ), mildly impaired left ventricular ejection fraction (LVEF > 40% and < 55%) or asymptomatic valvular disease 42 . Asymptomatic valvular disease was defined as at least mild aortic valve insufficiency or mild mitral valve insufficiency with mild thickening of the mitral valve. Asymptomatic cardiac abnormality with preserved ejection fraction was defined as HF-B with LVEF ≥ 55% 42 .
Data analysis
Statistical analyses were performed using SPSS Statistics version 21.0 (IBM Corp., Armonk, NY, USA). Continuous data were analyzed using the Mann-Whitney U-test for intergroup differences. Continuous data are reported as median with interquartile range (IQR). The Kruskal-Wallis test was used to analyze differences between more than two groups of continuous data. Dichotomous data were analyzed using the chi-square or Fisher's exact test for intergroup differences, reported as n (%). Associations between FMD and PE, metabolic syndrome risk factors and obstetric parameters were analyzed using uni-and multivariable linear regression. A two-sided P-value of < 0.05 was considered statistically significant. Based on findings of Melchiore et al. 13 on the prevalence of HF-B at 1 year postpartum in formerly preterm pre-eclamptic women (41%) compared with controls (6%), and on our observations 14 in the first year after pre-eclamptic gestation (25%) compared with controls (7%), the sample size needed was estimated using a prevalence of HF-B of 33% in formerly pre-eclamptic women and 6% in controls. The required sample size was calculated using a desired power of 0.80 and a two-sided alpha of 0.05. A minimum of 33 participants for each group was necessary for determining statistical significance. PE is a vascular disease of heterogeneous origin. To compensate for possible larger heterogeneity in hemodynamic assessments in formerly pre-eclamptic women than in controls, we aimed to include measurements of two formerly pre-eclamptic women for every one healthy parous control in the analysis.
RESULTS
Characteristics of the formerly pre-eclamptic and control groups are presented in Table 1 . The formerly pre-eclamptic group was on average 4 years younger compared with the control group (P < 0.01). Moreover, more women with a history of PE were obese (18% vs 3%, P < 0.05) and used antihypertensive medication (18% vs 0%, P < 0.01). Formerly pre-eclamptic women underwent postpartum measurement at a shorter median postpartum interval than the control group (5.3 (IQR, 4.4-6.4) vs 8.3 (IQR, 6.6-9.9) years, P ≤ 0.01). Birth weight was lower in the formerly pre-eclamptic group compared with the control group (1615 (IQR, 1034-2513) vs 3260 (IQR, 3000-3690) g; P ≤ 0.01). Forty out of 67 women in the formerly pre-eclamptic group had a subsequent pregnancy (60%), of which 17 (43%) had recurrent PE.
Formerly pre-eclamptic vs control group
Cardiovascular and metabolic variables are presented in Table 2 . Incidence of HF-A was eight-fold higher in the formerly pre-eclamptic group compared with the control group (24% vs 3%, P < 0.01). Of the HF-A variables, obesity was more prevalent in the formerly pre-eclamptic group as compared with controls.
HF-B was more common in formerly pre-eclamptic women as compared with controls (25% vs 8%, P ≤ 0.05). In formerly pre-eclamptic women with HF-B, none had previous myocardial infarction, 6% had left ventricular (LV) hypertrophy, 65% had concentric remodeling, 29% had mildly impaired LVEF and 6% had asymptomatic valve disease. Of the three controls with HF-B, none had previous myocardial infarction or LV hypertrophy, one had concentric remodeling, two had mildly reduced LVEF, and none had asymptomatic valve disease. As shown in Table 2 , the formerly pre-eclamptic group had higher SBP and HR compared with controls. DBP, MAP, SV, CO, LVEDV, LVEF, EA ratio, LVM index and RWT did not differ between the groups.
Formerly pre-eclamptic women had lower FMD compared with controls (6.12% (IQR, 4.82-8.30%) vs 8.22% (IQR, 5.79-11.33%), P < 0.01), whereas baseline diameter of the brachial artery was similar.
Of the metabolic syndrome variables, fasting insulin and HOMA were significantly higher and HDL significantly lower in the formerly pre-eclamptic group compared with the control group.
A subsequent pregnancy after the index one in the formerly pre-eclamptic group did not affect the prevalence of HF-A or HF-B, nor FMD or its component measurements, or metabolic syndrome variables (Tables S1 and S2 ).
The associations between FMD and PE, metabolic risk factors and obstetric parameters are presented in Table 3 . On univariable analysis, history of PE, postpartum interval, primiparity, impaired fasting insulin and obesity were associated with FMD peak percentage. The multivariable linear regression model showed R 2 = 0.33. In the multivariable model, history of PE remained associated significantly with FMD, with β = −1.88 (95% CI, −3.59 to −0.18). Moreover, impaired fasting insulin had a significant β of −1.63 (95% CI −3.21 to −0.05). The other variables, i.e. postpartum interval, primiparity, age, diabetes mellitus, hypertension, obesity, dyslipidemia and microalbuminuria, were not associated significantly with FMD on multivariable analysis. Table 4 presents the cardiovascular and metabolic syndrome variables in formerly pre-eclamptic women, subdivided according to those without HF, those with cardiovascular risk factor (HF-A) and those with functional or structural cardiac abnormality (HF-B). Of the cardiovascular variables, SBP, DBP and MAP were significantly higher in the HF-A compared with the no-HF subgroup; HR did not differ between these subgroups. Of the cardiac indices, only LVEF was significantly different (lower) in the HF-A compared with the no-HF subgroup. The HF-B subgroup had higher SBP, DBP and MAP compared with the no-HF subgroup; HR did not differ between these subgroups. Of the cardiac indices, LVEF was lower in the HF-B compared with the no-HF subgroup, and RWT was higher in the HF-B subgroup compared with both the no-HF and HF-A subgroups.
No HF vs HF-A vs HF-B
The baseline diameter of the brachial artery was comparable between the three subgroups. Moreover, FMD (%), FMD peak diameter and shear rate did not differ between the subgroups. Of the metabolic syndrome variables, fasting glucose, fasting insulin, HOMA and triglycerides were significantly higher in the HF-A subgroup compared with the no-HF subgroup. Moreover, more women in the HF-A subgroup had untreated hypertension and were using antihypertensive medication compared with the no-HF subgroup. Fasting insulin and HOMA were higher in the HF-B compared with the no-HF subgroup. Furthermore, more women in the HF-B subgroup were using antihypertensive medication compared with the no-HF subgroup.
DISCUSSION
To the best of our knowledge, this is the first demonstration of the assumed association between endothelial dysfunction, measured by FMD, and prevalence of HF-B after pre-eclampsia. First, we showed that formerly pre-eclamptic women have lower endothelium-dependent FMD compared with women with a history of only normotensive gestation, indicating attenuated endothelial function in the formerly pre-eclamptic group. Moreover, compared with controls, formerly pre-eclamptic women had an eight-fold higher prevalence of cardiovascular risk factor (HF-A) and three-fold higher prevalence of HF-B. Nonetheless, we did not observe any association between endothelial dysfunction and the prevalence of HF-A or HF-B in formerly pre-eclamptic women.
PE is associated with endothelial dysfunction that may persist during the first years after PE 7, 9, 10, 12, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . In this study, we found that at least 4 years postpartum, endothelial function, as indicated by FMD, was significantly lower in formerly pre-eclamptic women than in healthy controls, which is in line with earlier findings [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] and in contrast with other studies with a follow-up period of at least 10 years 20 . We also found that PE was associated independently with reduced FMD after correction for metabolic risk factors, as was insulin.
Vessel dilation is mediated by endothelium-dependent release of nitric oxide (NO) in response to reactive hyperemia and increased endothelial shear stress occurring after deflation of a perfusion-obstructive cuff 19, 34, 36 . As such, healthy endothelium has an important vasoactive function in stabilizing blood pressure intrinsically in response to alterations in flow, by the production of rapidly released short-acting NO, which instantly lowers underlying vessel muscle tone 34, 45 . On the one hand, shallow FMD may therefore reflect impaired endothelial function. On the other hand, in general, the observed decreased endothelial function after PE can also originate from impaired bioavailability of NO, restricted vasodilatory capacity due to mechanical changes stiffening the arterial wall or diminished signaling in smooth-muscle cells 46 . A few postpartum studies have showed reduced FMD originating from NO-dependent mechanisms, suggesting a less prominent effect of vascular stiffening in hampering FMD 21, [26] [27] [28] . However, one study observed that formerly pre-eclamptic women had reduced endothelium-dependent and NO-mediated FMD, as compared with controls 23 . Moreover, endothelial function could be normalized by aerobic exercise 28 . Even though we did not perform FMD with NO donor administration, given the young age of the cohort, endothelial dysfunction is most likely the cause of reduced FMD in the formerly pre-eclamptic group 21 . Impaired FMD is considered a strong predictor for cardiovascular events, independent of other traditional risk factors, and may be an important mediator between PE and the two-to seven-fold increased risk of remote CVD at a relatively young age 4, [47] [48] [49] . A meta-analysis by Inaba et al. showed that a 1% decrease in FMD is related to an 8% increased risk of CVD events in population-based convenience cohort studies 49 . Moreover, several studies showed impaired FMD in symptomatic stages of HF (i.e. HF-C or -D) 50 . Therefore, we expected to find a positive relationship between impaired FMD after PE and HF-B. In our cohort, we did not find such a relationship; although not expected, this is in line with the findings of a study by Muiesan et al., in which FMD was studied in relation to different LV geometric patterns in hypertensive patients 51 . They observed that the presence of endothelial dysfunction was not associated with differences in LV geometric patterns, suggesting that independent and different mechanisms may account for the presence of LV hypertrophy and endothelial dysfunction 51 . Moreover, the use of antihypertensive medication in the HF-B subgroup may also have attenuated the differences in endothelial function between the HF-B subgroup and the HF-A and no-HF subgroups. Antihypertensive treatment may reverse cardiac remodeling, enhance cardiac function and improve endothelial function, by reducing afterload or shear stress, or by their antioxidant activity 52, 53 . The role of changes in morphological, mechanical and functional properties of peripheral conduit arteries in relation to HF still needs to be elucidated.
This study has several limitations that should be taken into account. First, most of the formerly pre-eclamptic women were of European ethnic origin. Therefore, our results might not be fully generalizable to women of other ethnic origins. Second, HF is a cluster of different entities that are likely to have different physiological backgrounds that might have influenced our findings. However, we used the currently used definition of the AHA in the hope that this gives an accurate reflection of HF-B. Dividing the HF-B group into subgroups would have resulted in very low sample sizes with insufficient power. Subdividing the formerly pre-eclamptic women into three subgroups and therefore reducing the number of women per group increased the type 1 error risk. In anticipation of this, we analyzed our data non-parametrically. Despite smaller numbers, we did detect clinically relevant significant differences, which also shed light on the pathophysiological course of cardiac adjustments in women at risk for CVD. Therefore, it would be useful in future studies to include more women. Third, both groups had different recruitment procedures as healthy women do not routinely visit a gynecologist in The Netherlands. Therefore, we had to recruit controls by advertisement. It could be that women who replied had subtle signs of CVD that led them to question their risk. However, they may also have been concerned about their health, which could suggest that they have a healthy lifestyle. Moreover, controls had a longer postpartum interval, which might also induce certain bias as postpartum recovery can take, in certain cases, a few months to complete. However, it is not known at what interval it is optimal to perform cardiovascular screening. In this study, short-term pregnancy effects were excluded.
In conclusion, we showed lower FMD in formerly pre-eclamptic women 5-8 years postpartum as compared with women with a history of healthy pregnancy. Formerly pre-eclamptic women had an eight-fold higher prevalence of HF-A and a three-fold higher prevalence of HF-B compared with controls. However, no difference in FMD was found between formerly PE patients with HF-B and those without, suggesting different mechanisms underlying the subclinical stages of HF.
